Xencor (NASDAQ:XNCR) had its price target decreased by Nomura to $28.00 in a research note released on Thursday morning. Nomura currently has a neutral rating on the biopharmaceutical company’s stock.
A number of other research analysts have also commented on XNCR. Zacks Investment Research raised Xencor from a sell rating to a hold rating in a report on Saturday, March 17th. Leerink Swann reissued an outperform rating and set a $36.00 price objective on shares of Xencor in a report on Wednesday, March 28th. Cantor Fitzgerald reissued a buy rating and set a $37.00 price objective on shares of Xencor in a report on Thursday, March 29th. BidaskClub raised Xencor from a buy rating to a strong-buy rating in a report on Friday, March 9th. Finally, ValuEngine raised Xencor from a hold rating to a buy rating in a report on Monday, April 2nd. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Xencor has an average rating of Buy and a consensus target price of $35.17.
XNCR opened at $28.41 on Thursday. Xencor has a fifty-two week low of $18.55 and a fifty-two week high of $34.63. The stock has a market cap of $1,542.72, a PE ratio of -27.06 and a beta of 1.51.
In other Xencor news, insider Edgardo Baracchini, Jr. sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $30.89, for a total value of $1,235,600.00. Following the sale, the insider now owns 40,000 shares of the company’s stock, valued at approximately $1,235,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Paul A. Foster sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $26.03, for a total value of $260,300.00. Following the completion of the sale, the insider now directly owns 12,419 shares in the company, valued at approximately $323,266.57. The disclosure for this sale can be found here. In the last three months, insiders have sold 105,000 shares of company stock worth $3,101,550. 4.03% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Great West Life Assurance Co. Can grew its holdings in Xencor by 158.9% in the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 4,005 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in Xencor in the 3rd quarter valued at approximately $201,000. UBS Asset Management Americas Inc. acquired a new stake in Xencor in the 4th quarter valued at approximately $205,000. Landscape Capital Management L.L.C. acquired a new stake in Xencor in the 4th quarter valued at approximately $220,000. Finally, Two Sigma Advisers LP acquired a new stake in Xencor in the 4th quarter valued at approximately $278,000. 79.49% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3342790/nomura-cuts-xencor-xncr-price-target-to-28-00.html.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.